The Diagnosis and Treatment of Sjögren's Syndrome.

BACKGROUND Sjögren's syndrome is one of the more common inflammatory rheumatological diseases, with a prevalence of at least 0.4% in Germany. METHODS This review is based on pertinent articles retrieved by a selective search in PubMed. Special attention is drawn to updated classification criteria and current treatment recommendations. RESULTS Sjögren's syndrome has a wide variety of presentations, ranging from the local involvement of exocrine glands with keratoconjunctivitis sicca and xerostomia (the leading signs of the disease) to the systemic, extraglandular involvement of multiple organs. Fatigue also markedly worsens the patients' quality of life. Serologic testing reveals antinuclear auto-antibodies (anti-Ro/ SSA and anti-La/SSB) as well as rheumatoid factors. The histological hallmark of the disease is focal lymphocytic infiltration in otherwise normal-appearing glandular acini. The disease also markedly elevates the risk of non-Hodgkin lymphoma of the B-cell series, which arises in about 5% of patients. Primary Sjögren's syndrome (pSS) differs from the secondary form (sSS), which appears in the setting of another autoimmune disease, particularly systemic lupus erythematosus (15-36%), rheumatoid arthritis (20-32%), and limited or progressive systemic sclerosis (11-24%). Disease-modifying therapy is reserved for patients with systemic involvement; there is limited evidence for its efficacy. Because of the complexity of this disease, some of its clinical manifestations may require interdisciplinary treatment. CONCLUSION The main considerations in the interdisciplinary care of patients with Sjögren's disease are measures to improve quality of life, pharmacological and non-pharmacological treatments to keep disease activity in check, and management of the risk of lymphoma. Future therapeutic approaches must take the heterogeneity of the disease into account.

[1]  L. Criswell,et al.  2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts , 2017, Arthritis & rheumatology.

[2]  K. Sivils,et al.  Genetics in Sjögren Syndrome. , 2016, Rheumatic diseases clinics of North America.

[3]  T. Dörner,et al.  The Prevalence of Dental Implants and Related Factors in Patients with Sjögren Syndrome: Results from a Cohort Study , 2016, The Journal of Rheumatology.

[4]  J. Garrigue,et al.  Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial , 2016, European journal of ophthalmology.

[5]  T. Witte,et al.  Sjögren-Syndrom , 2016, DMW Deutsche Medizinische Wochenschrift.

[6]  D. Cornec,et al.  [Clinical usefulness of salivary gland ultrasonography in Sjögren's syndrome: Where are we now?]. , 2016, La Revue de medecine interne.

[7]  X. Mariette,et al.  Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations , 2016, Expert review of clinical immunology.

[8]  B. Cochener,et al.  The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review , 2015, Clinical Reviews in Allergy & Immunology.

[9]  E. Matteson,et al.  Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies. , 2015, Rheumatology.

[10]  R. Jonsson,et al.  Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling , 2015, Arthritis & rheumatology.

[11]  Ami A. Shah,et al.  Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome , 2015, Arthritis & rheumatology.

[12]  J. Buyon,et al.  The clinical spectrum of autoimmune congenital heart block , 2015, Nature Reviews Rheumatology.

[13]  Philippe Ravaud,et al.  EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide , 2015, RMD Open.

[14]  A. Shahane,et al.  The epidemiology of Sjögren’s syndrome , 2014, Clinical epidemiology.

[15]  R. Zhong,et al.  Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis , 2014, Annals of the rheumatic diseases.

[16]  J. Pepose,et al.  Rethinking dry eye disease: a perspective on clinical implications. , 2014, The ocular surface.

[17]  B. Kostov,et al.  Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). , 2014, Rheumatology.

[18]  P. Ravaud,et al.  Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI) , 2014, Annals of the rheumatic diseases.

[19]  P. Ravaud,et al.  Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort , 2013, PloS one.

[20]  F. Hiepe,et al.  Neurologische Manifestationen bei Kollagenosen , 2012, Zeitschrift für Rheumatologie.

[21]  M. Dalakas,et al.  Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms. , 2012, Journal of autoimmunity.

[22]  B. Segal,et al.  Primary Sjogren’s syndrome: cognitive symptoms, mood, and cognitive performance , 2012, Acta neurologica Scandinavica.

[23]  J. Pers,et al.  Treatment of primary Sjögren syndrome , 2012, Nature Reviews Rheumatology.

[24]  J. Anaya,et al.  HLA and Sjögren's syndrome susceptibility. A meta-analysis of worldwide studies. , 2012, Autoimmunity reviews.

[25]  T. Dörner,et al.  Fatigue and depression predict physician visits and work disability in women with primary Sjögren's syndrome: results from a cohort study. , 2012, Rheumatology.

[26]  H. Worthington,et al.  Interventions for the management of dry mouth: topical therapies. , 2011, The Cochrane database of systematic reviews.

[27]  A. Villa,et al.  Risk factors and symptoms associated with xerostomia: a cross-sectional study. , 2011, Australian dental journal.

[28]  L. Criswell,et al.  Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. , 2011, Arthritis and rheumatism.

[29]  R. Jonsson,et al.  Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome , 2011, Annals of the rheumatic diseases.

[30]  D. Pisetsky.  Antinuclear antibodies in healthy people: the tip of autoimmunity's iceberg? , 2011, Arthritis research & therapy.

[31]  M. Crow,et al.  Activation of the type I interferon pathway in primary Sjogren's syndrome. , 2010, Journal of autoimmunity.

[32]  Mimi Y. Kim,et al.  Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine , 2010, Annals of the rheumatic diseases.

[33]  B. Segal,et al.  Oral involvement in primary Sjögren syndrome. , 2008, Journal of the American Dental Association.

[34]  P. Emery,et al.  Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study , 2008, Annals of the rheumatic diseases.

[35]  H. Moutsopoulos.  Sjögren’s Syndrome or Autoimmune Epithelitis? , 2007, Clinical immunology and immunopathology.

[36]  P Rosenthal,et al.  Gas-permeable scleral contact lens therapy in ocular surface disease. , 2000, American journal of ophthalmology.

[37]  H. Haga,et al.  Renal involvement in primary Sjögren's syndrome. , 2000, QJM : monthly journal of the Association of Physicians.

[38]  R. Matthay,et al.  Pulmonary manifestations of Sjögren's syndrome. , 1998, Clinics in chest medicine.

[39]  H. Worthington,et al.  Interventions for the management of dry mouth: non-pharmacological interventions. , 2013, The Cochrane database of systematic reviews.